Attached files
file | filename |
---|---|
8-K - FORM 8-K - Horizon Therapeutics Public Ltd Co | d408180d8k.htm |
EX-5.1 - OPINION OF COOLEY LLP - Horizon Therapeutics Public Ltd Co | d408180dex51.htm |
EX-99.1 - CONSENT AND AMENDMENT - Horizon Therapeutics Public Ltd Co | d408180dex991.htm |
Exhibit 99.2
***Text Omitted and Filed Separately with the Securities and Exchange Commission.
Confidential Treatment Requested Under
17 C.F.R. Sections 200.80(b)(4) and 240.24b-2
To: | Horizon Pharma AG |
Kägenstrasse 17
CH-4153 Reinach
Switzerland
Mundipharma Medical Company
Mundipharma House, 5th Floor
14 Par-la-Ville Road
PO Box HM 2332
Hamilton, HM JX
Bermuda
06 October 2011
Dear Sirs
Exclusive Distribution Agreement, dated March 24, 2009 (the EDA), by and between Horizon Pharma AG (previously Nitec Pharma AG) (Horizon) and Mundipharma International Corporation Limited (Mundipharma); the Manufacturing and Supply Agreement dated March 24, 2009 (the MSA), by and between Horizon and Mundipharma Medical Company (MMCo) and the Letter Agreement dated 2nd March 2011 by and between Horizon, Mundipharma and MMCo (First Letter Agreement).
In order to clarify certain of the parties rights and obligations under the EDA, MSA and Letter Agreement, and to ensure the supply of Product for Mundipharmas forthcoming study into the treatment of Polymyalgia Rheumatica (PMR Study) pursuant to the EDA and the First Letter Agreement, Horizon, Mundipharma and MMCo, intending to be legally bound, agree as set forth below. Capitalized terms used but not otherwise defined in this letter agreement shall have the meanings provided in the EDA.
PMR Study.
Horizon shall supply Product in accordance with the specification in Appendix 1 to Mundipharma as requested so that Mundipharma may initiate the PMR Study. Mundipharmas requirement to initiate dosing of first patient in the PMR Study as set out in the First Letter Agreement between the parties shall be amended to prior to [...***...] to accommodate Horizons input into the PMR Study design and request for additional study sites.
Except as expressly amended and supplemented by this letter, the EDA, MSA and First Letter Agreement shall remain in full force and effect in accordance with their respective terms. Please note your acceptance of the terms of this letter agreement by signing below. This letter agreement may be signed in counterparts, each of which shall be deemed an original, all of which taken together shall be deemed one instrument.
*** Confidential Treatment Requested
Yours faithfully | ||
Mundipharma International Corporation Limited | ||
By: |
/s/ Douglas Docherty | |
Name: |
Douglas Docherty | |
Title: |
General Manager |
Agreed to and accepted as of the date first set forth above:
Horizon Pharma AG | Horizon Pharma AG | |||||
By: | /s/ Timothy P. Walbert |
By: | /s/ Hans-Peter Zobel | |||
Name: | Timothy P. Walbert | Name: | Hans-Peter Zobel | |||
Title: | Managing Director | Title: | Managing Director |
Mundipharma Medical Company | ||
By: |
/s/ Douglas Docherty | |
Name: |
Douglas Docherty | |
Title: |
General Manager |
APPENDIX 1
[...***...]
*** Confidential Treatment Requested